Literature DB >> 1183427

Antiepileptic and prophylactic effects of tetrahydrocannabinols in amygdaloid kindled cats.

J A Wada, A Wake, M Sato, M E Corcoran.   

Abstract

Acute administration of delta8-tetrahydrocannabinol (delta8-THC) or delta9-THC failed to affect partially developed or fully developed kindled amygdaloid seizures in cats. However, delta9-THC was quite effective in suppressing focal AD in the stimulated amygdala when administered very early in kindling, before the development of any clinical manifestations. This finding suggested that chronic administration of delta9-THC during kindling might block the process of seizure development, which was supported by the observation that three of four cats failed to kindle when treated with the drug. The cat that failed to be protected by delta9-THC was also insensitive to the general electroclinical effects of moderately high doses of delta9-THC. The prophylactic activity of delta9-THC is in contrast to the ineffectiveness of diphenylhydantoin, a drug whose anticonvulsant activity is often compared with that of THC.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1183427     DOI: 10.1111/j.1528-1157.1975.tb06080.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  12 in total

1.  Marijuana use and the risk of new onset seizures.

Authors:  J C Brust; S K Ng; A W Hauser; M Susser
Journal:  Trans Am Clin Climatol Assoc       Date:  1992

Review 2.  Control of excessive neural circuit excitability and prevention of epileptic seizures by endocannabinoid signaling.

Authors:  Yuki Sugaya; Masanobu Kano
Journal:  Cell Mol Life Sci       Date:  2018-05-08       Impact factor: 9.261

Review 3.  Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.

Authors:  Evan C Rosenberg; Pabitra H Patra; Benjamin J Whalley
Journal:  Epilepsy Behav       Date:  2017-02-09       Impact factor: 2.937

4.  Slim evidence for cannabinoids for epilepsy.

Authors:  John W Miller
Journal:  Epilepsy Curr       Date:  2013-03       Impact factor: 7.500

Review 5.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 6.  The Potential Proconvulsant Effects of Cannabis: a Scoping Review.

Authors:  Eric E Kaczor; Kevin Greene; Jennifer Zacharia; Laura Tormoehlen; Mark Neavyn; Stephanie Carreiro
Journal:  J Med Toxicol       Date:  2022-03-29

Review 7.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

8.  Cannabidiol for Treatment of Childhood Epilepsy-A Cross-Sectional Survey.

Authors:  Kerstin A Klotz; Andreas Schulze-Bonhage; Victoria San Antonio-Arce; Julia Jacobs
Journal:  Front Neurol       Date:  2018-09-07       Impact factor: 4.003

Review 9.  Cannabidiol in the Treatment of Epilepsy: A Focused Review of Evidence and Gaps.

Authors:  Guilherme Diogo Silva; Felipe Borelli Del Guerra; Maira de Oliveira Lelis; Lécio Figueira Pinto
Journal:  Front Neurol       Date:  2020-10-19       Impact factor: 4.003

Review 10.  Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases.

Authors:  Dhanush Haspula; Michelle A Clark
Journal:  Int J Mol Sci       Date:  2020-10-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.